ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of medicines focusing on central nervous system disorders. The company has a portfolio of product including its drug, NUPLAZID (pimavanserin), which has been approved by the U.S. Food and Drug Administration for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist preferentially targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors.
  • TickerACAD
  • ISINUS0042251084
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

An increasingly favourable environment allows ACADIA PHARMACEUTICALS to improve to Neutral

The independent financial analyst theScreener just upgraded the general evaluation of ACADIA PHARMACEUTICALS (US), a company active in the Biotechnology industry. As regards its fundamental valuation, the title confirms its rating of 3 out of 4 stars while its market behaviour remains as risky. theScreener believes, however, that a more enabling environment allows the title to increase its general evaluation to Neutral. As of the analysis date June 8, 2021, the closing price was USD 26.57 and its expected value was estimated at USD 22.69.

Jonathan Moreland

InsiderInsights Daily Ratings Report: April 30, 2021

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

ullish Tape Despite Inconsistencies Despite the bulls still being in control, we have several ongoing concerns and we cannot rule out the potential for a pullback. Below we highlight developments that are inconsistent with a major bottom in equities that suggests the broad equity market is not yet out of the woods. · S&P 500 Short-Term Levels. We continue to respect the bullish tape, however the S&P 500 remains in the 2855-2900 resistance zone while forming a bearish rising wedge pattern. This pattern results in a breakdown roughly 70% of the time. Still, support at 2760 would need ...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

ullish Tape Despite Inconsistencies Despite the bulls still being in control, we have several ongoing concerns and we cannot rule out the potential for a pullback. Below we highlight developments that are inconsistent with a major bottom in equities that suggests the broad equity market is not yet out of the woods. · S&P 500 Short-Term Levels. We continue to respect the bullish tape, however the S&P 500 remains in the 2855-2900 resistance zone while forming a bearish rising wedge pattern. This pattern results in a breakdown roughly 70% of the time. Still, support at 2760 would need ...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 Getting Long-Term Oversold Note: We have suspended the Russell grids and Sector comments this week due to heightened volatility. Major indexes broke below the key support levels we were watching on the Nasdaq Composite (8,264), S&P 500 (2,855), DJI (24,681) and Russell 2000 (1,448), ushering-in additional downside. We view these levels as logical areas of potential short-term resistance moving forward. Clues that a breakdown was increasingly likely started coming as early as Thursday, when the KBW Bank index broke below key $89 support we outlined last week. Friday's widening move in h...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

MSCI ACWI, STOXX 600 Breaking Out The market continues to feed off of optimism surrounding the US-China “phase one” trade deal. Boris Johnson's UK election victory has added an additional tailwind, particularly in the UK and Europe, where the UK's FTSE 250 and the STOXX Europe 600 indexes are breaking out to all-time highs. At some point the euphoria is likely to wear off, but with continued global bullish developments, it remains our belief that pullbacks should be bought and that global equities are in the early stages of a broad-based advance. • Sector Relative Strength Rankings (RS...

Jonathan Moreland

InsiderInsights Daily Ratings Report: April 30, 2021

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

An increasingly favourable environment allows ACADIA PHARMACEUTICALS to improve to Neutral

The independent financial analyst theScreener just upgraded the general evaluation of ACADIA PHARMACEUTICALS (US), a company active in the Biotechnology industry. As regards its fundamental valuation, the title confirms its rating of 3 out of 4 stars while its market behaviour remains as risky. theScreener believes, however, that a more enabling environment allows the title to increase its general evaluation to Neutral. As of the analysis date June 8, 2021, the closing price was USD 26.57 and its expected value was estimated at USD 22.69.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch